secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-07-22T11:00:18+00:00
Accession:  0001437749-26-024037
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals' subsidiary selected by DARPA for negotiation of potential award for SPARC-TMS trial
--------------------------------------------------------------------------------

- NRX Defense Systems received DARPA letter selecting its proposal for negotiation of a potential award for SPARC-TMS phase 2/3 trial.
- Trial combines robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
- NRX-101 previously received FDA Breakthrough Therapy Designation; trial approved by FDA and posted on ClinicalTrials.gov (NCT07227103).
- Study sites include Harvard McLean Hospital, HOPE Therapeutics clinics, and Walter Reed National Military Medical Center.
- Selection does not constitute a final award; subject to successful negotiation of definitive terms with DARPA/DSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/0001437749-26-024037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-024037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer